Company news

ANI Pharmaceuticals, Inc. news in 2026

ANI Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.

View company

ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results

November 5, 2026

ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business

November 5, 2026

ANI Pharmaceuticals to Present at Upcoming November Investor Conferences

November 3, 2026

ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8: 00 a.m. ET

October 23, 2026

ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release Capsules

October 19, 2026

ANI Pharmaceuticals Announces Positive Phase 4 Open-Label, Single-Arm SYNCHRONICITY Clinical Trial Results Presented as Late Breaking Oral Presentation at the American Academy of Ophthalmology 2026 Annual Meeting

October 12, 2026

ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting

September 30, 2026

ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension

September 23, 2026

ANI Pharmaceuticals to Present at September Investor Conferences

September 3, 2026

ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors

August 24, 2026

ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results

August 7, 2026

ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8: 00 a.m. ET

July 23, 2026

ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter

July 16, 2026

ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis

July 13, 2026

ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

May 26, 2026

ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance

May 8, 2026

ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8: 00 a.m. ET

April 24, 2026

ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity

April 20, 2026

ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules

April 12, 2026

ANI Pharmaceuticals Announces FDA Approval and Launch of Isosorbide Mononitrate Tablet

April 7, 2026

ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology

April 7, 2026

ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance

February 27, 2026

ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 8: 00 a.m. ET

February 13, 2026

ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities

January 12, 2026

ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 5, 2026

Calls in 2026

Decks in 2026